SolAeroMed Announces Completion of Phase IIA Proof of Concept Recruitment for S-1226

CALGARY, Alberta, November 24, 2015 – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, today announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site

Read more

top